Ukko

Executive Summary

Ukko is an Israeli preclinical biotech company leveraging AI-driven computational protein design to develop hypoallergenic variants of food allergens for immunotherapy. By engineering proteins that educate the immune system without triggering allergic reactions, the company aims to treat life-threatening allergies such as peanut and tree-nut sensitivities. Founded in 2020 and based in Tel Aviv, Ukko operates at the intersection of artificial intelligence and immunology, with a focus on creating safer, more effective treatments for food allergies. The company is currently in the preclinical stage and has not disclosed total funding or valuation, reflecting an early but innovative pipeline. Despite the nascent stage, Ukko's approach holds promise in addressing a large unmet medical need, as current treatment options are limited and often involve strict avoidance or emergency interventions. The company's success will depend on advancing its lead candidates through preclinical studies, securing partnerships, and demonstrating proof-of-concept in human trials.

Upcoming Catalysts (preview)

• Q3 2026Preclinical Proof-of-Concept Data for Lead Hypoallergenic Candidate40% success
• Q4 2026Series A or Seed Funding Announcement50% success
• Q2 2027Strategic Partnership for AI-Driven Protein Design Platform35% success